The contribution of CD40/CD40L axis in inflammatory bowel disease: An update

Frontiers in Immunology

Volumn 6, Issue OCT, 2015, Pages

  Senhaji, Nezha ^a   Kojok, Kevin ^b   Darif, Youssef ^c   Fadainia, Christophe ^b   Zaid, Younes ^b  

^a HASSAN II UNIVERSITY   (Morocco)

^b MONTREAL HEART INSTITUTE   (Canada)

^c Université HASSAN II   (Morocco)

Author keywords

CD40; CD40L; Immunity; Inflammatory bowel disease; Signaling pathways

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; INTERLEUKIN 2;

B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CYTOKINE PRODUCTION; DENDRITICCELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84946553623     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00529     Document Type: Short Survey

References (44)

1. Sobczak M, Fabisiak A, Murawska N, Wesolowska E, Wierzbicka P, Wlazlowski M, et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep (2014) 66(5):766-75. doi: 10.1016/j.pharep.2014.04.005.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol (2003) 3(7):521-33. doi:10.1038/nri1132.
3. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 117(3):514-21. doi:10.1172/JCI30587.
4. Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol (2008) 14(3):338-47. doi:10.3748/wjg.14.338.
5. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 369(9573):1641-57. doi:10.1016/S0140-6736(07)60751-X.
6. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology (2011) 140(6):1785-94. doi:10.1053/j.gastro.2011.01.055.
7. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 140(6):1756-67. doi:10.1053/j.gastro.2011.02.016.
8. Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today (1993) 14(11):559-64. doi:10.1016/0167-5699(93)90188-Q.
9. Lee JR, Koretzky GA. Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes. Eur J Immunol (1998) 28(12):4188-97. doi:10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B.
10. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation (2002) 106(8):981-6. doi:10.1161/01.CIR.0000027107.54614.1A.
11. Stokes KY, Calahan L, Hamric CM, Russell JM, Granger DN. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol (2009) 296(3):H689-97. doi:10.1152/ajpheart.00962.2008.
12. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol (2007) 597:131-51. doi:10.1007/978-0-387-70630-6_11.
13. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 58(1):4-43. doi:10.1007/PL00000776.
14. Paulie S, Koho H, Ben-Aissa H, Hansson Y, Lundblad ML, Perlmann P. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. II. Identification of the cellular target structures by immunoprecipitation and SDS-PAGE analysis. Cancer Immunol Immunother (1984) 17(3):173-9. doi:10.1007/BF00205482.
15. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 8(5):1403-10.
16. Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J (1992) 11(12):4313-21.
17. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 112(10):1506-20. doi:10.1172/JCI200319301.
18. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol (2002) 103(1):54-62. doi:10.1006/clim.2001.5172.
19. Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol (2004) 4(10):775-86. doi:10.1038/nri1462.
20. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 21(5):293-300. doi:10.1016/j.smim.2009.05.012.
21. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A (2009) 106(3):876-81. doi:10.1073/pnas.0810769106.
22. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 13(2):139-45. doi:10.1038/nm1551.
23. Jacobson EM, Huber AK, Akeno N, Sivak M, Li CW, Concepcion E, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun (2007) 8(3):205-14. doi:10.1038/sj.gene.6364375.
24. Barbe-Tuana FM, Klein D, Ichii H, Berman DM, Coffey L, Kenyon NS, et al. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes (2006) 55(9):2437-45. doi:10.2337/db05-1673.
25. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 2(4):301-6. doi:10.1038/86302.
26. Suto A, Nakajima H, Ikeda K, Kubo S, Nakayama T, Taniguchi M, et al. CD4(+)CD25(+) T-cell development is regulated by at least 2 distinct mechanisms. Blood (2002) 99(2):555-60. doi:10.1182/blood. V99.2.555.
27. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med (2001) 194(4):427-38. doi:10.1084/jem.194.4.427.
28. Guiducci C, Valzasina B, Dislich H, Colombo MP. CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol (2005) 35(2):557-67. doi:10.1002/eji.200425810.
29. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev (2006) 212:256-71. doi:10.1111/j.0105-2896.2006.00423.x.
30. Liu Z, Colpaert S, D'Haens GR, Kasran A, de Boer M, Rutgeerts P, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol (1999) 163(7):4049-57.
31. Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol (1999) 94(11):3279-84. doi:10.1111/j.1572-0241.1999.01538.x.
32. Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, et al. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol (2002) 14(3):237-41. doi:10.1097/00042737-200203000-00006.
33. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut (2003) 52(10):1435-41. doi:10.1136/gut.52.10.1435.
34. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis (2003) 18(2):142-7. doi:10.4049/jimmunol.164.11.6005.
35. Liu Z, Geboes K, Colpaert S, Overbergh L, Mathieu C, Heremans H, et al. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol (2000) 164(11):6005-14. doi:10.4049/jimmunol.164.11.6005.
36. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 183(2):693-8. doi:10.1084/jem.183.2.693.
37. Clegg CH, Rulffes JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, et al. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol (1997) 9(8):1111-22. doi:10.1093/intimm/9.8.1111.
38. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 176(4):2617-24. doi:10.4049/jimmunol.176.4.2617.
39. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology (2005) 129(1):50-65. doi:10.1053/j.gastro.2005.05.013.
40. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet (2008) 17(R2):R116-21. doi:10.1093/hmg/ddn246.
41. Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther (2005) 22(2):111-22. doi:10.1111/j.1365-2036.2005.02526.x.
42. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 93(6):2499-504. doi:10.1073/pnas.93.6.2499.
43. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol (1998) 160(5):2158-65.
44. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science (1993) 261(5126):1328-30. doi:10.1126/science.7689748.